US · guidance
CMS Pub. 100-03, ch. 1, § 190.1
Histocompatibility Testing
Histocompatibility testing involves the matching or typing of the human leucocyte
antigen (HLA). This testing is safe and effective when it is performed on patients:
A. In preparation for a kidney transplant;
B. In preparation for bone marrow transplantation;
C. In preparation for blood platelet transfusions (particularly where multiple
infusions are involved; or
D. Who are suspected of having ankylosing spondylitis.
This testing is covered under Medicare when used for any of the indications listed in A,
B, and C and if it is reasonable and necessary for the patient.
It is covered for ankylosing spondylitis in cases where other methods of diagnosis would
not be appropriate or have yielded inconclusive results. Request documentation
supporting the medical necessity of the test from the physician in all cases where
ankylosing spondylitis is indicated as the reason for the test.
History
(Rev. 12112; Issued: 06-29-23; Effective: 07- 31-23; Implementation: 07-31- 23)
Provenance
- Source
- cms.gov
- Retrieved
- 2026-08-25
- Edition
- iom-2026-08-25
- Content hash
e267f822face3dd00e8e397770a9fda2715a13c211a62a041bb3d3b62f9604b1
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.